Form 4: RVMD General Counsel Executes Pre-Planned Stock Sale

Revolution Medicines General Counsel, Jeff Cislini, executed a pre-planned sale of 12,000 common shares following the exercise of stock options.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc., reported transactions involving the company's common stock.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
• On October 17, 2025, Cislini acquired 12,000 shares of common stock by exercising stock options at a price of $36.57 per share.
• Concurrently, on October 17, 2025, Cislini disposed of 12,000 shares of common stock at a price of $55.00 per share.
• Following these reported transactions, Cislini beneficially owns 50,425 shares of common stock, which includes 43,910 restricted stock units.
• Cislini also holds 18,000 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction executed under a pre-planned 10b5-1 trading plan. This type of transaction is generally considered neutral as it does not typically signal new material information about the company's prospects.

Positives

• The General Counsel realized a gain from the exercise of stock options and subsequent sale of shares.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, material non-public information.

Negatives

• An officer selling shares, even under a 10b5-1 plan, can sometimes be perceived as a slight negative by some investors, though the pre-planned nature mitigates this concern.

Future Outlook

This filing, a Form 4, does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider trading and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by an officer, while pre-planned, could be viewed with slight caution by some, but the 10b5-1 plan mitigates concerns about opportunistic selling based on new information.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 plan. This type of filing typically does not provide new material information that would alter an investment thesis or warrant a change in recommendation. Investors should continue to evaluate Revolution Medicines based on its fundamental business performance, pipeline developments, and broader market conditions.

Keywords

Revolution Medicines, RVMD, Jeff Cislini, General Counsel, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan